These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17190845)

  • 1. Oral varenicline for smoking cessation.
    Zierler-Brown SL; Kyle JA
    Ann Pharmacother; 2007 Jan; 41(1):95-9. PubMed ID: 17190845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Varenicline--a new chance for smokers?].
    Goniewicz ML; Koszowski B; Czogała J; Sobczak A
    Przegl Lek; 2007; 64(10):899-902. PubMed ID: 18409337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation.
    Faessel HM; Obach RS; Rollema H; Ravva P; Williams KE; Burstein AH
    Clin Pharmacokinet; 2010 Dec; 49(12):799-816. PubMed ID: 21053991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers.
    Burstein AH; Fullerton T; Clark DJ; Faessel HM
    J Clin Pharmacol; 2006 Nov; 46(11):1234-40. PubMed ID: 17050788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH; Clark DJ; O'Gorman M; Willavize SA; Brayman TG; Grover GS; Walsky RL; Obach RS; Faessel HM
    J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.
    Ericson M; Löf E; Stomberg R; Söderpalm B
    J Pharmacol Exp Ther; 2009 Apr; 329(1):225-30. PubMed ID: 19126781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Varenicline--a new drug for smoking cessation].
    Tønnesen P
    Ugeskr Laeger; 2007 Nov; 169(47):4051-2. PubMed ID: 18078657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study.
    Feng B; Obach RS; Burstein AH; Clark DJ; de Morais SM; Faessel HM
    Clin Pharmacol Ther; 2008 Apr; 83(4):567-76. PubMed ID: 17971819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varenicline: new drug. Smoking cessation: no better than nicotine.
    Prescrire Int; 2006 Dec; 15(86):210-2. PubMed ID: 17165237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varenicline and bupropion sustained-release combination therapy for smoking cessation.
    Ebbert JO; Croghan IT; Sood A; Schroeder DR; Hays JT; Hurt RD
    Nicotine Tob Res; 2009 Mar; 11(3):234-9. PubMed ID: 19246427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking cessation therapy considerations for patients with chronic kidney disease.
    Manley HJ; Stack NM
    Nephrol Nurs J; 2008; 35(4):357-63, 394; quiz 364. PubMed ID: 18782998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers.
    Park PW; Casiano EM; Escoto L; Claveria AM
    Curr Med Res Opin; 2011 Oct; 27(10):1869-75. PubMed ID: 21838412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varenicline (CHANTIX): a stop-smoking pill.
    ORL Head Neck Nurs; 2006; 24(4):18-9. PubMed ID: 17390707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
    Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
    J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
    Faessel HM; Smith BJ; Gibbs MA; Gobey JS; Clark DJ; Burstein AH
    J Clin Pharmacol; 2006 Sep; 46(9):991-8. PubMed ID: 16920893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Varenicline: an aid to smoking cessation therapy].
    Perez-Bogerd S; Sternon J
    Rev Med Brux; 2007; 28(6):523-6. PubMed ID: 18265811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.